Oxford University Innovation and Parkwalk Advisors announced today that the University of Oxford Isis Fund II has raised over £2 million, exceeding its funding target, and will close to new investors. The fund achieved its initial target in less than four weeks and will close at almost twice that level.
Nightstar, which was spun out in 2014 raising £12 million from Syncona, the venture arm of the Wellcome Trust, has received additional finance from its key investors to advance the company’s clinical choroideremia programme.
AIM-listed Summit plc has filed for a proposed offering of American Depositary Shares on the NASDAQ Global Market in the United States.
Project to be funded under the DTI/BBSRC/MRC LINK Programme in Applied Genomics.
Oxitec Limited announces the completion of its second funding round of £1.3m, led by Oxford Capital Partners. The existing investors, East Hill Advisors, LLC from Boston and the University of Oxford (through the Isis College Fund), have made further investments in the company as part of this round. Oxford Capital Partners invested £550,000.
Oxford Immunotec, the T cell diagnostics company, announced today that it has closed a £7M series B private equity financing.
Emergent Biosolutions and the University of Oxford form joint venture to develop an advanced tuberculosis vaccine with funding from Wellcome Trust and Aeras Global TB Vaccine Foundation.
Oxford spin-outs have been busy raising finance. A total of nearly £50 million has been secured so far this year by some of the 50 companies spun-out by Oxford University Innovation from the University of Oxford, including those mentioned below.
£1.75m business support for next generation of UK clean tech pioneers.
Oxford University Innovation, the University of Oxford’s technology transfer company, achieved increased revenues of £5.6 million in the last financial year, up 18 per cent from the previous year.
